mechanical-circulatory-support
(3)
Supira Medical
Supira Medical is a clinical-stage cardiovascular device company in Los Gatos, California, building a next-generation percutaneous ventricular assist device (pVAD). Incubated inside Amr Salahieh's Shifamed innovation hub and led by CEO Nitin Salunke, the Supira System is a low-profile (10F), high-flow heart pump designed to give the heart temporary circulatory support during high-risk coronary interventions and cardiogenic shock, with the goal of moving more blood through a smaller sheath than the incumbent devices. The company raised a $120M oversubscribed Series E in March 2025 and won FDA approval to begin its SUPPORT II pivotal trial in 2026.
Procyrion, Inc.
Procyrion, Inc. is a Houston-based medical device company developing Aortix, a catheter-delivered percutaneous mechanical circulatory support (pMCS) pump. About the width of a pencil, Aortix is anchored in the descending aorta where it unloads the failing heart while boosting blood flow to the kidneys, targeting acute decompensated heart failure and cardiorenal syndrome. The device holds FDA Breakthrough Device Designation and is in the DRAIN-HF pivotal IDE trial after closing a $57.7M Series E in February 2024.
J. Eduardo Rame
J. Eduardo Rame is a Philadelphia cardiologist who treats the sickest hearts in medicine - patients in the final stage of heart failure who depend on pumps, transplants and the chance their own muscle can be coaxed back to life. As the Louis R. Dinon MD Professor and enterprise chief of Advanced Cardiac and Pulmonary Vascular Disease at Jefferson Health, he runs an integrated division built around recovery rather than replacement. Yale-trained in biophysics, Oxford-trained in health economics and Harvard-trained in medicine, he spent a decade founding Penn's mechanical circulatory support program before bringing that work to Jefferson. His research on left ventricular assist devices, including the landmark MOMENTUM 3 trial, has been cited more than 12,000 times.